6533b7d7fe1ef96bd1267aa8
RESEARCH PRODUCT
Splenic Littoral Cell Hemangioendothelioma in a Patient With Crohn's Disease Previously Treated With Immunomodulators and Anti-TNF Agents: A Rare Tumor Linked to Deep Immunosuppression
Ada Maria FlorenaMatilde CacciatoreGianfranco CocorulloMaria CappelloIvana Bravatàsubject
6-MercaptopurineMalePathologymedicine.medical_specialtyColonic Diseasemedicine.medical_treatmentAzathioprineSplenic NeoplasmHemangioendotheliomaHemangiomaImmunosuppressive AgentImmunocompromised HostImmunologic FactorCrohn Disease6-Mercaptopurine; Azathioprine; Colonic Diseases; Crohn Disease; Gastrointestinal Agents; Hemangioendothelioma; Hemangioma; Humans; Ileal Diseases; Immunologic Factors; Immunosuppressive Agents; Male; Middle Aged; Splenic Neoplasms; Tumor Necrosis Factor-alpha; Immunocompromised Host; GastroenterologyAzathioprineGastrointestinal AgentMedicineGastrointestinal agentCrohn's diseaseHepatologyTumor Necrosis Factor-alphabusiness.industryGastroenterologyImmunosuppressionMiddle Agedmedicine.diseaseSplenic NeoplasmHemangioendotheliomaImmunologyIleal DiseaseTumor necrosis factor alphaHemangiomabusinessHumanmedicine.drugdescription
Th e risk of malignancy in Crohn ’ s disease (CD) has been well described. Moreover, immunomodulators, uch as azathioprine (AZA) and 6-mercaptopurine (6-MP), and biological agents, such as infl iximab and adalimumab, may promote carcinogenesis ( 1 – 3 ). Splenic littoral cell tumors are recently described tumors of vascular origin composed of endothelial cells, with typical microscopic and immunohistochemical features of splenic sinus lining cells ( 4 ). Clinical findings are not specific, and outcome is unpredictable but usually benign, although a few cases with a malignant behavior have been reported ( 5,6 ). We report a 58-year-old Caucasian man with a long history of ileocolonic CD.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2011-10-01 | American Journal of Gastroenterology |